PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
13 December 2022 - 11:00PM
Business Wire
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
changing the treatment paradigm for devastating diseases, today
announced that Daphne Zohar, Founder and Chief Executive Officer,
will present at the 41st Annual J.P. Morgan Healthcare Conference
on Tuesday, January 10, 2023, at 2:15 p.m. PST / 5:15 p.m. EST. A
webcast of the presentation will be available at
https://investors.puretechhealth.com.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221213005209/en/
PureTech’s Founder and Chief Executive
Officer, Daphne Zohar, will present at the 41st Annual J.P. Morgan
Healthcare Conference on Tuesday, January 10, 2023, at 2:15 p.m.
PST / 5:15 p.m. EST. (Photo: Business Wire)
About PureTech Health PureTech is a biotherapeutics
company dedicated to changing the treatment paradigm for
devastating diseases. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 28 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received both
U.S. FDA clearance and European marketing authorization and a third
(KarXT) that will soon be filed for FDA approval, as of the most
recent update by the Company. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points based on unique
insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements This
press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to our upcoming presentation at
the 41st Annual J.P. Morgan Healthcare Conference and our future
prospects, developments and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not
limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2021 filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221213005209/en/
PureTech Public Relations
publicrelations@puretechhealth.com Investor Relations
IR@puretechhealth.com
EU Media Ben Atwell, Rob Winder +44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media Nichole Sarkis +1 774 278 8273
nichole@tenbridgecommunications.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024